ARTICLE | Clinical News
Keflex Pulsys: Phase III start
July 2, 2007 7:00 AM UTC
MBRK (formerly Advancis Pharmaceutical Corp.) will begin a double-blind, non-inferiority Phase III trial in >=600 patients to compare 1,200 mg Keflex PULSYS once daily vs. 250 mg of Keflex cephalexin...